Total RNA from A549, NCI-H23, NCI-H358, NCI-H661, and HCC827 lung cancer cells; MDA-MB-231, MDA-MB-468, and MCF-7 breast cancer cells; PC-3 prostate cancer cells; and CACO-2, DLD-1, and HT-29 colon cancer cells cultured in serum-free medium was reverse transcribed and amplified using specific primers for serglycin (Figure 1(a)). This evidence concerns the gene SRGN and breast carcinoma.